Clearmind Medicine announces publication on MEAI potential in weight loss

Clearmind Medicine announced that a new article published by Baraghithy et al, revealed promising results from a recent study on 5-methoxy-2-aminoindane for combating obesity. The study was meticulously conducted by a team of experts led by Prof. Joseph Tam, head of the Obesity and Metabolism Laboratory at the School of Pharmacy in the Hebrew University of Jerusalem. Key findings from the study include:Weight loss: MEAI significantly reduced diet-induced obesity in mice by decreasing fat mass while preserving lean mass. Improved Metabolism: MEAI significantly improved glycemic control by reducing hyperglycemia, glucose intolerance and hyperinsulinemia, highlighting its therapeutic potential in regulating glucose metabolism. Fatty liver disease: MEAI decreased fatty liver by lowering liver triglyceride and cholesterol levels, mainly through inhibiting new lipid synthesis and reducing fat accumulation. Increased Energy Expenditure: MEAI increased energy expenditure and fat utilization while maintaining a similar food consumption. Activity: MEAI increased activity-specific energy expenditure without overstimulation supporting its potential to impact energy balance. These findings are based on the results from Clearmind Medicine’s study aimed to investigate the ability of MEAI to modulate metabolism and counteract obesity.